Effect of endothelin-1 on astrocytic protein content.
The astrocytic endothelin (ET) receptors, ET(A) and ET(B), modulate calcium signaling and the astrocytic gap junctional network. The nonselective ET receptor ligand ET-1 inhibits gap junction permeability, an effect that can be blocked by tolbutamide. This mechanism may play a role in pathophysiological conditions such as ischemic stroke, characterized by elevated tissue ET-1 levels and hypertrophic-appearing reactive astrocytes. Therefore, the effect of ET-1 on cellular protein content was investigated in confluent once-passaged rat astrocyte cultures under serum-free conditions, by the Lowry method. Gap junction permeability was determined by the dye transfer technique. ET-1 prevented the decrease in astrocytic protein content observed in controls. The effect of ET-1 on cellular protein content was most pronounced in cultures seeded at high density, but it was attenuated in ET(B)-deficient (sl/sl) astrocytes. This effect could be blocked by the nonselective ET antagonist LU 302872 (10 micro M), as well as by the protein synthesis inhibitor cycloheximide (10 micro M). This increase in astrocytic protein content was inhibited by the ATP-sensitive K(+) channel blocker tolbutamide, which also antagonized the ET-1-induced reduction of gap junction permeability and reversed the morphological changes observed in astrocytes upon ET-1 treatment. Cytosine arabinoside (10 micro M), a DNA synthesis blocker, inhibited the ET-1-induced BrdU uptake without affecting the ET-1-induced increase in astrocytic protein content. To conclude, ET-1 induces an increase in astrocytic protein content as well as changes in astrocyte morphology in vitro. This hypertrophic response involves uncoupling of the astrocytic gap junctional network and is not dependent on DNA synthesis.
Max-Planck-Institut für Experimentelle Medizin, Göttingen, Germany.
Martin
M
Hasselblatt
Marion
M
Bunte
Ralf
R
Dringen
Arantxa
A
Tabernero
José M
JM
Medina
Christian
C
Giaume
Anna-Leena
AL
Sirén
Hannelore
H
Ehrenreich
D000818:Animals; D000963:Antimetabolites / Q000493:pharmacokinetics; D000964:Antimetabolites, Antineoplastic / Q000494:pharmacology; D001253:Astrocytes / Q000166:cytology / Q000187:drug effects* / Q000378:metabolism*; D001973:Bromodeoxyuridine / Q000493:pharmacokinetics; D002478:Cells, Cultured; D003513:Cycloheximide / Q000494:pharmacology; D003561:Cytarabine / Q000494:pharmacology; D065128:Endothelin Receptor Antagonists; D019332:Endothelin-1 / Q000494:pharmacology*; D017629:Gap Junctions / Q000187:drug effects / Q000502:physiology; D007004:Hypoglycemic Agents / Q000494:pharmacology; D009419:Nerve Tissue Proteins / Q000378:metabolism; D011422:Propionates / Q000494:pharmacology; D011500:Protein Synthesis Inhibitors / Q000494:pharmacology; D011743:Pyrimidines / Q000494:pharmacology; D051381:Rats; D011922:Rats, Mutant Strains; D017208:Rats, Wistar; D017466:Receptors, Endothelin / Q000378:metabolism; D014044:Tolbutamide / Q000494:pharmacology
D000963:Antimetabolites; D000964:Antimetabolites, Antineoplastic; D065128:Endothelin Receptor Antagonists; D019332:Endothelin-1; D007004:Hypoglycemic Agents; C113044:LU 224332; D009419:Nerve Tissue Proteins; D011422:Propionates; D011500:Protein Synthesis Inhibitors; D011743:Pyrimidines; D017466:Receptors, Endothelin; D003561:Cytarabine; D014044:Tolbutamide; D003513:Cycloheximide; D001973:Bromodeoxyuridine